Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,232,378
  • Shares Outstanding, K 21,100
  • Annual Sales, $ 141,100 K
  • Annual Income, $ 12,560 K
  • 36-Month Beta 0.91
  • Price/Sales 35.84
  • Price/Cash Flow 63.56
  • Price/Book 8.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.86
  • Number of Estimates 1
  • High Estimate 0.86
  • Low Estimate 0.86
  • Prior Year 0.55
  • Growth Rate Est. (year over year) +56.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
213.09 +16.37%
on 07/31/18
255.38 -2.90%
on 08/14/18
+26.23 (+11.83%)
since 07/17/18
3-Month
184.02 +34.76%
on 05/22/18
255.38 -2.90%
on 08/14/18
+56.84 (+29.74%)
since 05/17/18
52-Week
123.11 +101.43%
on 08/29/17
255.38 -2.90%
on 08/14/18
+121.36 (+95.85%)
since 08/17/17

Most Recent Stories

More News
Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.

LGND : 247.98 (+3.47%)
ILMN : 325.88 (-0.34%)
MNK : 34.69 (+1.61%)
EVOK : 2.44 (+3.39%)
Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB

Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB

LGND : 247.98 (+3.47%)
SIVB : 320.76 (-0.20%)
CLF : 9.86 (+0.72%)
ERII : 9.10 (+2.02%)
HEAR : 26.39 (+0.50%)
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?

Is (LGND) Outperforming Other Medical Stocks This Year?

LGND : 247.98 (+3.47%)
Pick These 5 Profitable Stocks With Impressive Returns

Profitability analysis helps in calculating the total expenses borne and total revenues generated by a company

LGND : 247.98 (+3.47%)
SIVB : 320.76 (-0.20%)
CLF : 9.86 (+0.72%)
ERII : 9.10 (+2.02%)
HEAR : 26.39 (+0.50%)
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

LGND : 247.98 (+3.47%)
VRTX : 176.08 (+0.64%)
GILD : 72.92 (-3.53%)
BIIB : 345.22 (+0.67%)
5 Sizzling Stocks Played Down by Hedge Funds in Q2

We pick five large cap top-ranked stocks that have been ignored by hedge funds in Q2.

AAPL : 217.58 (+2.00%)
LGND : 247.98 (+3.47%)
FTNT : 76.50 (-0.12%)
MOH : 134.83 (+0.51%)
FB : 173.80 (-0.52%)
AMZN : 1,882.22 (-0.23%)
PAYC : 139.87 (+1.16%)
After Yesterday's Rally of 2.46% Shares Could Potentially Pullback

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $243.39 to a high of $248.99. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of...

LGND : 247.98 (+3.47%)
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

CELG : 90.37 (+0.24%)
LGND : 247.98 (+3.47%)
ILMN : 325.88 (-0.34%)
GILD : 72.92 (-3.53%)
Ligand Pharm Shares Up 21.5% Since SmarTrend's Buy Recommendation (LGND)

SmarTrend identified an Uptrend for Ligand Pharm (NASDAQ:LGND) on June 21st, 2018 at $199.56. In approximately 2 months, Ligand Pharm has returned 21.45% as of today's recent price of $242.36.

LGND : 247.98 (+3.47%)
Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View

Ligand (LGND) beats both earnings and sales estimates in the second quarter of 2018. The company raised its guidance for 2018.

SPPI : 22.78 (-0.26%)
LGND : 247.98 (+3.47%)
NVS : 83.04 (+1.03%)
AMGN : 197.42 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 255.66
1st Resistance Point 251.82
Last Price 247.98
1st Support Level 240.43
2nd Support Level 232.88

See More

52-Week High 255.38
Last Price 247.98
Fibonacci 61.8% 204.85
Fibonacci 50% 189.24
Fibonacci 38.2% 173.64
52-Week Low 123.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar